Navigation Links
Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Date:6/1/2009

KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer

NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) yesterday announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstract #4081, entitled, "Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer," was presented yesterday in a poster during the Gastrointestinal Cancer -- Colorectal session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida.

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line metastatic colon cancer were randomized to receive capecitabine (Xeloda(R)), an approved drug for metastatic colon cancer, at a dose of 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1-14 every 21 days, plus either perifosine or placebo at 50 mg daily. Treatment was continued until progression. The study enrolled a total of 38 patients, of which 35 patients were evaluable for response (20 patients on the capecitabine + perifosine arm and 15 patients on the capecitabine + placebo arm). The three patients not evaluable for response were all in the capecitabine + placebo arm; 2 patients were inevaluable due to toxicity (days 14, 46) and 1 patient was inevaluable due to a new malignancy on day 6.

The median prior treatment regimens was two, with prior treatment regimens as follows: 91%
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
2. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
3. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
4. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
5. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that Steven ... and David Haen , Vice President of ... corporate overview at two significant investment conferences in ... industries: the FBR & Co. Second Annual Health ...
(Date:9/1/2015)... 1, 2015 Pressure BioSciences, Inc. (OTCQB: ... the development and sale of broadly enabling, pressure ... worldwide life sciences industry, today announced the publication ... Company,s PCT Platform could play a significant role ... role is based on PCT,s unique ability to ...
(Date:9/1/2015)... , September 1, 2015 ... company, today announces that it has appointed Hilde ... Non-Executive Directors to its Board of Directors, effective immediately. ... years of experience in pharma and biotech and is ... a Sanofi company. Previously her role was Vice President ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
... Pricing of $500 Million of Senior Notes in Connection with... -- ARDEE, Ireland, Sept. 24 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Misonix, Inc. (Nasdaq: MSON ), a ... technology, which worldwide is used for acute health conditions, ... ended June 30, 2010 financial results on Tuesday, September ... Officer and Richard Zaremba, Senior VP and Chief Financial ...
Cached Medicine Technology:Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 2Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 3Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 4Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 5Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 6Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 7Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 8Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern 2
(Date:9/1/2015)... ... ... Agriculture innovation, urban farming, local food access, and sourcing from sustainable and ... 4th Annual Sustainable Agriculture Conference : “Innovation and the Rise of Local Food,” ... keynotes Pierre Sleiman, founder and CEO of Go Green Agriculture, and Daron “Farmer D” ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of Laboratory Instruments in accordance with GMP requirements“ , featuring Ed Szczesny (Quality ... 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, qualification, and the ...
(Date:9/1/2015)... ... September 01, 2015 , ... Suzanne Bakken, PhD, RN, ... the Institute of Medicine (IOM) of the National Academies. , She is the ... of Nursing. A member of the Institute of Medicine since 2006, Bakken also ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... 1,500 investor-families have received permanent green cards (I-829 petition approval) from the USCIS ... petition is the final step of the EB-5 visa process for immigrant investors ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
Breaking Medicine News(10 mins):Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4
... vaccine called the TAT vaccine has been developed in Italy ... And more importantly it has had a 71% success rate ... human testing and this may be the brightest hope for ... the Department of Virology at Italy’s National Health Institute and ...
... Allergy and asthma patients can now breathe easy. Literally. A ... be effective in improving the quality of life and has ... findings of this study are reported in the latest issue ... M. Walker, PhD, of the Imperial College School of Medicine ...
... the importance of sleep for memory and learning. It ... as fatigue and reduced alertness. ,A study ... allowing recovery sleep by Harvard Medical school researches. Subjects ... no improvement in task performance but those who were ...
... Have you ever wondered why your kids are so aggressive and ... over there is increasing concern over the way the children of ... looking for help. Things are no better in India. With the ... all at a very young age and many parents complain that ...
... researchers at the just concluded Indian science congress in New ... to combat anemia with iron fortification of crops. Almost 50% ... are anemic in India. While iron supplementation is expensive, fortification ... fight anemia in people is fairly cheaper, scientists say. ...
... pregnancy can lead to increased risk of heart problems ... environment contribute to several aspects of cardiovascular risks in ... ,People whose mothers starved during the first 13 ... their adult life, Starvation during mid or late pregnancy ...
Cached Medicine News:
Inquire...
Calss II Type B2 Biological Safety Cabinet...
External Calibration Only. Built-in RS232 Interface, Shimadzu WindowsDirect communication function. 120/240V A/C adapter....
... Semi-Micro balance. Built-in, motor-driven internal ... Performs Fully Automatic Self-Calibration when temperature ... intervals. Menu-selected weighing parameters, plug-in ... function keypads make this balance series ...
Medicine Products: